Among the clinically relevant mutations found in the tumour tissue, the MSH2 variant was the same as detected by germline testing, while the MLH1 and TP53 mutations were confirmed to be somatic by both the germline panel test and targeted Sanger sequencing. Here, TP53 is linked to neoplasm.